Loading company
Just reported
Q3 2026 results
From Bionano Genomics's results release of November 10, 2026; its quarterly report has since been filed.
Revenue
Actual
$8.3M
+12% y/y
+1.3% q/qGuided
$8.4M
midpoint
Within guide-1.5%EPS, GAAP
Actual
-$0.54
Guided
—
No guide given
Operating income, GAAP
Actual
-$6.5M
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue$31M – $33M+12% y/y Unchanged
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Bionano Genomics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.$153.8BA+
MDLNMedline Inc.$51.9BA
ALCAlcon Inc.$36.1BA
BLCOBausch & Lomb Corp$7.5BA-
ATRCAtriCure, Inc.$2.9BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now A
Built from Bionano Genomics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
